|Category:||Clinical Stage Biotech Company|
|Speaker:||Carsten Rudolph, CEO|
Ethris is developing mRNA-based therapeutics and vaccines to treat patients with (rare) respiratory disorders and infectious diseases.
Ethris’ novel, proprietary technology platform consisting of SNIM RNA , SNaP LNP and Stabilizer preventing LNP aggregation which affords multi-route, multi-cargo delivery options for intramuscular, inhaled or nasal administration and suitable for several genetic medicine payloads including mRNA and gene editing technologies
Download our company information
Tweets von https://twitter.com/ethris_mrna?lang=de